How to buy Imugene (IMU) shares
Learn how to easily invest in Imugene shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
How to buy shares in Imugene
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Imugene . Find the share by name or ticker symbol: IMU. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Imugene reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Imugene . Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Imugene stock price (ASX:IMU)Use our graph to track the performance of IMU stocks over time.
Imugene shares at a glance
|52-week range||$0.15 - $0.625|
|50-day moving average||$0.2045|
|200-day moving average||$0.3528|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.005|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Imugene stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Imugene price performance over time
|1 week (2022-06-02)||-11.76%|
|1 month (2022-05-12)||-6.25%|
|3 months (2022-03-11)||-40.00%|
|6 months (2021-12-10)||-70.87%|
|1 year (2021-06-11)||-56.52%|
|2 years (2020-06-12)||316.67%|
|3 years (2019-06-12)||837.50%|
|5 years (2017-06-09)||1,062.79%|
|Revenue TTM||$8.5 million|
|Gross profit TTM||$7.2 million|
|Return on assets TTM||-15.16%|
|Return on equity TTM||-25.36%|
|Market capitalisation||$965.1 million|
TTM: trailing 12 months
Imugene share dividends
We're not expecting Imugene to pay a dividend over the next 12 months.
Have Imugene 's shares ever split?
Imugene 's shares were split on a 1:7 basis on 11 November 2002. So if you had owned 7 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Imugene shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Imugene shares which in turn could have impacted Imugene 's share price.
Imugene share price volatility
Over the last 12 months, Imugene 's shares have ranged in value from as little as $0.15 up to $0.625. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Imugene 's is 2.261. This would suggest that Imugene 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Imugene in the news
Frequently asked questions
More guides on Finder
How to invest in the Bayrock Resources IPO
Everything we know about the Bayrock Resources IPO, plus information on how to buy in.
How to invest in the Critical Minerals Group IPO
Everything we know about the Critical Minerals Group IPO, plus information on how to buy in.
How to invest in the Chalkos Metals Limited IPO
Everything we know about the Chalkos Metals Limited IPO, plus information on how to buy in.
How to buy Cluey (CLU) shares
Steps to owning and managing Cluey shares.
How to buy Koba Resources (KOB) shares
Steps to owning and managing Koba Resources shares.
How to buy Rincon Resources (RCR) shares
Steps to owning and managing Rincon Resource shares.
How to buy Payright (PYR) shares
Steps to owning and managing Payright shares.
How to invest in the Iltani Resources IPO
Everything we know about the Iltani Resources IPO, plus information on how to buy in.
Bloom Impact Investing app review
Bloom Impact Investing offers exclusively climate impact investing, with direct climate action being the goal.
How to buy Kingfisher Mining (KFM) shares
Steps to owning and managing Kingfisher Mining shares.
Ask an Expert